Interleukin-8 and RANTES levels in patients with relapsing–remitting multiple sclerosis (RR-MS) treated with cladribine

Authors


Bartosik-Psujek Halina, Department of Neurology, Medical University, 8 Jaczewskiego Street, 20-090 Lublin, Poland
Tel.: +48-81-7425420
Fax: +48-81-7425431
e-mail: halbp@poczta.onet.pl

Abstract

Objective – Chemokines are involved in the pathogenesis of multiple sclerosis. The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines – interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted).

Materials and methods – Twenty-five patients with relapsing–remitting multiple sclerosis were treated with 2-chlorodeoxyadenosine (Cladribine), administered subcutaneously in 6 cycles repeated every 5 weeks. IL-8 and RANTES levels were measured by the enzyme-linked immunoassay (ELISA) method in serum and cerebrospinal fluid (CSF) before and after treatment.

Results – After Cladribine treatment the levels of IL-8 decreased significantly in CSF only, whereas the RANTES levels decreased significantly both in CSF and serum.

Conclusion – Our results suggest that Cladribine therapy might modify the circulating level of RANTES.

Ancillary